Navigation Links
Quark Reports Progress of siRNA Clinical Programs; 300 Patients Dosed With Quark Pharmaceuticals' siRNA Drugs In Multiple Fully Enrolled Clinical Trials
Date:11/19/2009

FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., the leader in siRNA therapeutics in clinicals, announced today that four of its siRNA R&D platform based programs have met clinical development milestones; patient enrollment was completed in three clinical studies and a new IND opened for ocular neuroprotection drug candidate QPI 1007:

  • Pfizer Inc., which licenses PF-4523655 from Quark, has completed enrollment in a Phase 2 study of PF-4523655 in patients with diabetic macular edema (DME). PF-4523655 is designed to inhibit the expression of the Quark's proprietary target RTP801, a gene involved in abnormal blood vessel development and leakage in the eye. Pfizer is also conducting a Phase 2 study of PF-4523655 in patients with age-related macular degeneration (AMD).
  • Quark has completed enrollment in two studies evaluating the safety of QPI-1002 in different patient populations following systemic administration. These include a Phase 1 study for the prevention of acute kidney injury (AKI) in patients undergoing major cardiovascular surgery, and Part A of a Phase 1/2 study in renal transplant patients for the prophylaxis of delayed graft function (DGF). QPI-1002, designed to temporarily inhibit the stress-response gene p53, is the first systemically administered siRNA drug to enter human clinical trials. Quark is poised to move forward with both programs in 2010.
  • Quark also announced that it expects to begin enrolling patients during the first quarter of 2010 under its open IND, in a Phase 1 study of the ocular neuroprotective agent QPI-1007. Quark's first siRNA drug candidate with proprietary siRNA structure, QPI-1007, has been evaluated in several models of ocular neuroprotection and shown to protect retinal ganglion cells in an increased ocular pressure preclinical model of glaucoma.

"Quark has maintained its leadership position in
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals to Present Data on its siRNA Therapeutic Programs in Kidney and Lung Diseases
2. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
3. Quark Pharmaceuticals Presents at Asia TIDES Conference
4. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
5. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
6. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
7. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
11. Quark Pharmaceuticals Appoints New Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Conkwest, Inc., ... developing the proprietary Natural Killer (NK) cell-line platform, ... Dr. Patrick Soon-Shiong , NantWorks founder, physician ... definitive agreement to purchase approximately $48 million of ... with the investment, he will be named Co-Chairman ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)...  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), a ... development of brachytherapy devices and medical isotopes for ... has filed a de novo submission ... marketing clearance for its patented Y-90 RadioGel(TM) device ... Drug and Cosmetic Act (the "Act").  ...
Breaking Medicine Technology:Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 2Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 3Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 4Conkwest Announces $50m In Strategic Investments And Appoints NantWorks Founder, Dr. Patrick Soon-Shiong As Co-Chairman Of The Board 5Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... not always keep hands injury-freeLAS VEGAS, Feb. 27 ... on the rise in recent years, with more than ... Many of those injuries might be prevented with better ... the 2009 Annual Meeting of the American Academy ...
... Fenofibrate treatment reduces,cardiovascular disease (CVD) ... the,composite of cardiovascular death, myocardial infarction, ... patients with type 2 diabetes and,atherogenic ... high triglyceride (2.3,mmol/L-200mg/dL or higher) and ...
Cached Medicine Technology:Experience Not Always the Best Prescription for Snowblowers 2Experience Not Always the Best Prescription for Snowblowers 3Experience Not Always the Best Prescription for Snowblowers 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 2Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 3Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 4Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 5Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study 6
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
(Date:12/24/2014)... The report “Stivarga (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... which is used in the treatment of colon or ... also prescribed to patients who suffer from advanced gastrointestinal ... a multi-kinase inhibitor and it blocks many enzymes which ...
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter TUESDAY, ... have abstained from sex for one year will be allowed to ... that would reverse a 31-year ban on donations from men who ... announced Tuesday its intention to release a new draft guidance in ... from gay men. The FDA is changing its policy based ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- A new, injectable ... and Drug Administration. The agency on Tuesday approved ... those who are overweight and have at least one ... 2 diabetes or high cholesterol. Patients taking the ... low-calorie diet and exercise regularly, the FDA noted. ...
(Date:12/24/2014)... Tara Haelle ... News) -- Teens are more likely to start smoking ... attention-deficit hyperactivity disorder (ADHD) or conduct disorder, new ... counsel families about the risk of substance use as ... Brinkman, research director at Cincinnati Pediatric Research Group, which ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... Washington University School of Medicine in St. Louis have ... it may sound, can be an essential approach to ... culture plates containing tumor cells to see if the ... one substance had scored a hit by inhibiting growth ...
... ... Food, Water and Essentials to about 300,000 Children and Families, , ... Port-au-Prince, Haiti (Vocus) February 9, 2010 -- One ... reached nearly 300,000 children and adults in the earthquake impact zone. , , , , ...
... insert them , TUESDAY, Feb. 9 (HealthDay News) -- Larger ... profit are more likely to use feeding tubes in patients ... prolong life or help with bed sores and other problems. ... more about which hospital you go to than a decision-making ...
... , , Give a ... Diabetes Kitchen" Cookbook , CHICAGO , Feb. 9 ... for the heart with the new cookbook "The Heart-Smart Diabetes Kitchen: Fresh, ... (ADA) and CanolaInfo. Whether you cook some of these recipes for love or ...
... Boston University,s Slone Epidemiology Center have found a direct ... 2 diabetes in African American women. The study, which ... , is the first prospective study to examine the ... 2 diabetes in a large, geographically diverse cohort of ...
... , , Passage of Problem-Riddled Health Freedom ... & Thousands of Jobs , BOISE, Idaho , ... laying the groundwork to oppose a non-existent federal health care law, ... to come.  AARP is calling the Idaho Health Freedom Act (House ...
Cached Medicine News:Health News:Researchers discover new way to kill pediatric brain tumors 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 2Health News:One Month after Major Quake, Ongoing Crises for Haitian Children 3Health News:Too Many With End-Stage Dementia Get Feeding Tubes 2Health News:Too Many With End-Stage Dementia Get Feeding Tubes 3Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 2Health News:Cook With Love This Valentine's Day With Heart-Smart Recipes 3Health News:Neighborhood socioeconomic status and diabetes 2Health News:Idaho House Moves State Closer to Health Care Disaster 2Health News:Idaho House Moves State Closer to Health Care Disaster 3Health News:Idaho House Moves State Closer to Health Care Disaster 4
... Electric Micro Sagittal Saw, ... 6 deg. arc. Head rotates ... any angle, and our unique ... slippage. Can also be purchased ...
... The Brasseler USA™ Battery ... quickly and efficiently determine ... STR-2000, STR-3000 Extended Run, ... Driver™, Battery Packs contain ...
... Brasseler USA™ 2002 Battery Charger is manufactured to ... 2002 Battery Charger can charge up to four ... The 2002 Charger is designed to operate on ... is a malfunction in the operation of the ...
... contain rechargeable nickel cadmium battery cells. Heat ... battery life. Strict adherence to recommended autoclave ... recommendations will shorten battery life. Warning: Battery ... of the Battery Packs to autoclave conditions ...
Medicine Products: